Interferon γ suppresses dentin sialophosphoprotein in oral squamous cell carcinoma cells resulting in antitumor effects, via modulation of the endoplasmic reticulum response

IOANNIS GKOUVERIS¹, NIKOLAOS G. NIKITAKIS², JAYA ASEERAVATHAM³ and KALU U.E. OGBUREKE³

¹Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA 90095, USA; ²Department of Oral Medicine and Pathology, School of Dentistry, National and Kapodistrian University of Athens, Athens 11527, Greece; ³Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center at Houston, Houston, TX 77054, USA

Received May 17, 2018; Accepted September 19, 2018

DOI: 10.3892/ijo.2018.4590

Abstract. The expression of proinflammatory cytokines in various malignant neoplasms is widely considered to represent the host immune response to tumor development. The role of interferon (IFN)γ in head and neck squamous cell carcinoma, and its association with endoplasmic reticulum (ER) stress pathways, remains a subject of ongoing investigation. Dentin sialophosphoprotein (DSPP), which is a member of the small integrin-binding N-linked glycoproteins family, has been implicated in malignant transformation and invasion of oral squamous cell carcinoma (OSCC). Recent studies have established matrix metalloproteinase (MMP)20 as the cognate MMP partner of DSPP. The present study examined the effects of IFNγ treatment on DSPP and MMP20 expression, ER stress, the unfolded protein response (UPR), and calcium (Ca) homeostasis regulatory mechanisms in OSCC cells. The OSC2 OSCC cell line was treated with IFNγ at specific time-points. At each time-point, the mRNA expression levels of DSPP and MMP20, and those of ER-stress-, UPR- and Ca homeostasis-associated proteins [78-kDa glucose-regulated protein (GRP78), sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA2b), inositol 1,4,5-trisphosphate receptor (IP3r), protein kinase R-like ER kinase (PERK) and inositol-requiring enzyme 1 (IRE1)], were assessed by reverse transcription-quantitative polymerase chain reaction. The protein expression levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), proliferating cell nuclear antigen (PCNA) and cytochrome c were analyzed by western blotting. Cell viability, apoptosis and migration were evaluated by MTT, Annexin V-fluorescein isothiocyanate flow cytometry and wound-healing assays, respectively. IFNγ treatment significantly downregulated the mRNA expression levels of the major ER stress regulator GRP78 and, to a lesser extent, the UPR-associated molecule IRE1; however, IFNγ had no significant effect on PERK. With regards to ER Ca homeostasis molecules, treatment with IFNγ downregulated the mRNA expression levels of SERCA2b and upregulated those of IP3r. Furthermore, DSPP and MMP20 mRNA expression levels were significantly reduced following IFNγ treatment. Notably, treatment with IFNγ hampered OSCC migration, reduced cell viability and PCNA protein expression, enhanced apoptosis, downregulated Bcl-2, and upregulated Bax and cytochrome c. Overall, IFNγ inhibited OSCC cell viability and migration, and increased apoptosis, possibly by regulating ER stress and UPR mechanisms. In addition, IFNγ-induced DSPP and MMP20 downregulation may correspond with alteration in ER Ca homeostasis.

Introduction

Oral squamous cell carcinoma (OSCC) is the sixth most common type of cancer worldwide (1). In the United States alone,  >50,000 new cases are diagnosed annually, resulting in ~10,000 cases of mortality (2,3). Surgery remains the main treatment option for patients with OSCC, since the currently available chemotherapeutic agents have proved to be of limited success. Therefore, the 5-year survival rate for patients with OSCC over the past four decades remains at 50-55%, despite novel treatment modalities (4,5). A better understanding of the biological nature of OSCC is required, in order to improve the effectiveness of chemotherapeutic intervention and, consequently, the survival of patients with OSCC.

IFNγ is an immune response-stimulating cytokine, which orchestrates several distinct cellular functions. Its role focuses on enhanced immune cell surveillance (6,7) and induction of the major histocompatibility complex response in numerous types of normal and neoplastic cells (8,9). IFNγ, which is secreted by activated T cells and natural killer cells, enhances macrophage...
activation, T helper cell (Th)1/Th2 balance, and regulates cellular proliferation and apoptosis (10). Furthermore, IFNγ has been reported to directly attack tumor cells by initiating a cascade of signaling mechanisms that modulate cell viability (11,12). Although the molecular basis of this action remains unclear, previous studies have proposed potential effects of IFNγ on endoplasmic reticulum (ER) stress proteins (13-15) and ER calcium (Ca) homeostasis channel pumps (16).

The ER is responsible for protein folding and targeting during protein synthesis, and represents the principal intracellular Ca storage, which is essential for Ca signaling pathways and the regulation of cellular Ca homeostasis (17,18). Sarco/endoplasmic reticulum Ca-ATPase (SERCA)-type pumps are the major carriers of Ca into the ER lumen, whereas inositol 1,4,5-trisphosphate receptors (IP3rs) are family proteins that drive Ca release channels (19). These Ca influx or efflux channels are regulated by Ca-dependent channnels, including 78-kDa glucose-regulated protein (GRP78), which bind or buffer intraluminal Ca (17,20).

ER homeostasis is a multifactorial process that is affected by numerous environmental factors, including the redox state, ischemia, nutrient and Ca level alterations, high protein synthesis rate, and inflammation (21). Persistent stimuli may disrupt proper ER function, thus leading to ER stress. This, in turn, may result in activation of a cascade of signaling molecules and pathways that constitute the unfolded protein response (UPR) (21,22). The main aim of the UPR is to arrest intraluminal accumulation and/or secretion of unfolded proteins and enhance degradation of misfolded proteins (23,24). Protein kinase R-like ER kinase (PERK), activating transcription factor (ATF)6 (α and β), and the kinase endoribonuclease inositol-requiring enzyme 1 (IRE1), constitute three ER transmembrane protein-sensors that detect alterations in ER homeostasis. Conversely, GRP78 is considered to be the master UPR chaperone that negatively regulates PERK, ATF6 and IRE1 functions (17,25). A nexus between ER stress and cancer has previously been highlighted; UPR alterations inactivation of a cascade of signaling molecules and pathways that constitute the unfolded protein response (UPR) (21,22). The main aim of the UPR is to arrest intraluminal accumulation and/or secretion of unfolded proteins and enhance degradation of misfolded proteins (23,24). Protein kinase R-like ER kinase (PERK), activating transcription factor (ATF)6 (α and β), and the kinase endoribonuclease inositol-requiring enzyme 1 (IRE1), constitute three ER transmembrane protein-sensors that detect alterations in ER homeostasis. Conversely, GRP78 is considered to be the master UPR chaperone that negatively regulates PERK, ATF6 and IRE1 functions (17,25). A nexus between ER stress and cancer has previously been highlighted; UPR alterations may prevent ER stress-induced apoptosis and help cancer cells survive in a otherwise demanding microenvironment (23). Other studies have also revealed that GRP78 cysteine oxidation favors cancer cell survival during stress (22), and SERCA activity has been reported as a potential target for cancer treatment (17).

Dentin sialophosphoprotein (DSP) is a member of the small integrin-binding ligand N-linked glycoproteins (SIBLINGs) family (26). Within the past decade, the expression of some members of the SIBLINGs family, along with their cognate matrix metalloproteinases (MMPs), have been detected in various types of cancer, including OSCC (27-31). Specifically, our previous studies have indicated that DSP expression is correlated with the transition of dysplastic oral premalignant lesions to OSCC, with tumor aggressiveness, and with the recurrence of OSCC at histologically negative (‘tumor-free’) surgical margins of primary OSCC (28-31). DSP is expressed in the cytoplasm and perinuclear perimeter of OSCC cells, with significantly elevated immunoreactivity in the cytoplasm of poorly differentiated OSCC cells (28).

Our recent study reported a novel finding, that matrix MMP20 is expressed and directly interacts with DSP in human OSCC tissues and cell lines (32). This finding established MMP20 as the cognate MMP partner of DSP (32). Furthermore, dentin sialoprotein (DSP), which is the cleaved N-terminal product of DSPP, interacts with MMP20 promoter proximal elements (32). An earlier report by Joshi et al demonstrated that DSPP silencing in OSCC cells results in MMP2, MMP3, MMP9, vascular endothelial growth factor, p53, Ki-67 and epidermal growth factor receptor downregulation, as well as altered cell morphology, cell proliferation, colony-formation and invasion of OSCC cells (33). In addition, DSPP silencing increases cisplatin sensitivity and enhances apoptosis of OSCC cells, whereas subcutaneous injection of OSCC xenografted Balb/c nude mice with DSPP-silenced OSCC cells results in attenuated tumor growth (33). Our recent report proposed a tumorigenic role for DSPP in OSCC cells, and presented a relationship between DSPP and the ER chaperone GRP78 (34). Furthermore, our report suggested a DSPP-associated modulatory effect on ER stress, Ca homeostasis and UPR proteins, including sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2b), IRE1, PERK and ATF6 (34).

The present study aimed to investigate the role of IFNγ signaling in DSP expression. The study aimed to elucidate a potential connection between this interaction and ER homeostasis, and suggested an alternative mechanism responsible for IFNγ-induced effects on OSCC cells. Therefore, the effects of IFNγ treatment on specific ER stress-associated proteins, including SERCA2b, IP3r, GRP78, IRE1 and PERK, were investigated in the OSC2 OSCC cell line, and its effects on tumor cell proliferation, migration and apoptosis were analyzed.

Materials and methods

**Human cell lines and culture conditions.** The previously characterized human OSCC cell line, OSC2, which was originally obtained from the American Type Culture Collection (Manassas, VA, USA) and routinely authenticated in our laboratory, was used for this study. Cells were cultured as a monolayer in Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1% penicillin/streptomycin and 500 ng/ml hydrocortisone (Sigma Aldrich; Merck KGaA, Darmstadt, Germany), and were maintained at 37°C in a humidified atmosphere containing 5% CO2. Recombinant human IFNγ was purchased from Abcam (Cambridge, MA, USA). For all experiments, OSC2 cells were plated and cultured for 48 h prior to the addition of IFNγ at a concentration of 500 U/ml for 24 or 48 h at 37°C. Time-points were chosen with regards to time-response experiments on interferon-regulated factor 1 (IRF1) mRNA expression following treatment with 500 U/ml IFNγ for 6, 12, 24 or 48 h.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.** Total RNA was extracted from cells using TRIzol® reagent (cat. no. 15596-026; Invitrogen; Thermo Fisher Scientific, Inc.), according to a standardized protocol, and the concentration of each sample was determined. The qSTAR qPCR primer pairs against human genes had the following sequences (5'-3'): IRF1, forward CGAATGCCTCCTGCAAGACA, reverse GCCCGAGCTCCGGAGAAACACGA; DSPF, forward CAACCATAGAGAAAGCAAACGCG, reverse ATTGTC; PERK, forward ATCCCCCATGGAAGCCAGCCCTG, reverse ACCGCGAGGACAAATGAT; SERCA2b, forward
TCATCTCCAGATCACCCGC, reverse GTCAGACCA GAACATATC; 5′; forward GGTTCATTTGGAAGTTAA TAAAG, reverse AATGCTCTAGTTGAACTCGTGTC; IRE1, forward CGGGAATTCC GCAGTCCTCAGCAGT; GRP78, forward TTGATATACACCCAAA ACTC, reverse TTTGCTGATATCCCTTTACAGT; and β-actin, forward GTTCCCTGACCTACACGCG and reverse ACCACCCGTGTGAGCCCA.

Total RNA (1 µg) was reverse transcribed using iScript RT Supermix (cat. no. 17088841; Bio-Rad Laboratories, Inc., Hercules, CA, USA), according to the manufacturer's protocol. qPCR was performed using synthesized cDNA on a qPCR machine using iTaq™ UniverSYBR® Green PCR Master Mix (cat. no. 1725124; Bio-Rad Laboratories, Inc.). PCR thermocycling was conducted as follows: 94°C for 5 min, followed by 40 cycles at 94°C for 30 sec, 60°C for 20 sec and 72°C for 40 sec, and a final extension step at 72°C for 5 min. A standard curve was generated from three serial dilutions of cDNA. Samples, including negative controls, were analyzed in triplicate, and PCR products were verified using dissociation curve analysis. mRNA expression levels were normalized to actin and were analyzed using Bio-Rad CFX manager software (Version 3.0; Bio-Rad Laboratories, Inc.).

**Western blot analysis.** Western blot analysis was performed as previously described (34). Briefly, cells were lysed and sonicated (20 kHz, 2x10 sec) in radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific, Inc.). Subsequently, equal amounts of protein (30-50 µg, depending on the particular protein), as determined by the Bradford protein assay method, were separated by 10% SDS-PAGE, and electrophoretically separated proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Inc.). Blotted membranes were then placed in blocking solution (PBS-0.5% Tween-20, Sigma-Aldrich; Merck KGaA) for 1 h at room temperature prior to probing with the following primary antibodies, which were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA): Mouse monoclonal B-cell lymphoma 2 (Bcl-2; cat. no. sc-7382, 1:250); mouse monoclonal Bcl-2-associated X protein (Bax; cat. no. sc-7480, 1:200); rabbit polyclonal cytochrome c (cat. no. sc-7159, 1:200) and rabbit polyclonal proliferating cell nuclear antigen (PCNA; cat. no. sc-7907, 1:200) overnight at 4°C. The membranes were washed thoroughly with PBS (Sigma Aldrich; Merck KGaA), and then incubated with goat polyclonal anti-rabbit immunoglobulin G (IgG) horseradish peroxidase-conjugated secondary antibody (cat. no. sc-2301, 1:3,000; Santa Cruz Biotechnology, Inc.), or anti-mouse IgG horseradish peroxidase-conjugated secondary antibody (cat. no. sc-2301, 1:3,000; Santa Cruz Biotechnology, Inc.) with agitation at room temperature for 1 h. β-actin (1:2,000) was used as a loading control (cat. no. sc-47778; Santa Cruz Biotechnology, Inc.). Proteins were visualized using an enhanced chemiluminescence (ECL) system (Pierce™ ECL; Thermo Fisher Scientific, Inc.) and band intensity was semi-quantified using ImageJ software 1.48 (National Institutes of Health, Bethesda, MD, USA).

**MTT assay.** Cell viability was assessed by detecting the conversion of MTT to formazan via mitochondrial oxidation.

IFNγ-treated and untreated OSC2 cells, at a density of 5x10³ cells/well, were incubated with 0.5 mg/ml MTT for 3 h at room temperature in 96-well plates after 24 and 48 h in culture. The formation of insoluble formazan purple crystals indicated the presence of viable cells. Crystals were dissolved in dimethyl sulfoxide and the optical density (OD) of the solutions was measured using a spectrophotometer at a wavelength of 570 nm. Assays were performed in triplicate and data are expressed as the means of OD values ± standard deviation.

**Apoptosis analysis by flow cytometry.** For apoptosis analyses, Annexin V/propidium iodide (PI; Sigma Aldrich; Merck KGaA) staining of IFNγ-treated and untreated OSC2 cells was conducted after 24 and 48 h. Briefly, cells were washed with 1X PBS and resuspended at 10⁶ cells/ml in Annexin V-binding buffer, before aliquoting the suspension into 100 µl/tube fractions. Subsequently, 5 µl Annexin V-fluorescein isothiocyanate (FITC) and 10 µl PI buffer were added to each tube and cells were incubated in the dark for 15 min at room temperature. Finally, 400 µl 1X Annexin V-binding buffer was added to each tube and flow cytometric analysis was conducted within 1 h. Samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Gates in the right angle scatter versus forward scatter diagrams were used to exclude debris. At least 100,000 events were collected prior to analysis. All flow cytometric data were analyzed using BD CellQuest Pro software (Version 5.0; BD Biosciences).

**Scratch wound-healing assay.** OSC2 cells were cultured until they reached 90% confluence in 35-mm dishes. Subsequently, scratches were generated using a sterile 200-µl pipette tip prior to cells being treated with IFNγ for 24 or 48 h. The border of the denuded area was immediately marked with a fine line, and cells were incubated in DMEM/F12 supplemented with 10% FBS. Images of the cell cultures were captured at 24 and 48 h using an inverted phase contrast microscope (Olympus Corporation, Tokyo, Japan). Assays were performed in duplicate.
Statistical analysis. Results from IFNγ-treated cells were compared with results from untreated (control) cells. Statistical analyses were performed using SPSS version 21 (IBM Corp., Armonk, NY, USA). Paired groups were compared using Student's t-test, whereas one-way analysis of variance was applied for the comparison of multiple groups, followed by post hoc pairwise comparisons with the application of Dunn's test. All experiments were performed in triplicate. P<0.05 was considered to indicate a statistically significant difference.

Results

IFNγ (500 U/ml) activates intracellular molecular signaling networks at specific time-points. The synthesis of IRF1 is induced by IFNγ (35). Therefore, to determine whether the selected dose of 500 U/ml IFNγ effectively activated intracellular molecular signaling pathways, alterations in the mRNA expression levels of IRF1 were monitored by RT-qPCR analyses in a time-dependent assay. As shown in Fig. 1, the mRNA expression levels of IRF1 exhibited a statistically significant time-dependent increase in cells treated for 24 and 48 h compared with the control cells (0 h). Since 24 and 48 h IFNγ treatment resulted in an increased IFNγ response, these time-points (24 and 48 h) and dose (500 U/ml) were selected for subsequent experiments.

IFNγ treatment downregulates DSPP, MMP20, GRP78, SERCA2b and IRE1, but upregulates IP3r and PERK in OSC2 cells. To evaluate the effects of IFNγ treatment on DSPP and MMP20, as well as on the ER stress response, UPR and Ca homeostasis, alterations in the mRNA expression levels of DSPP, MMP20, GRP78, SERCA2b, IP3r, PERK and IRE1 were determined by RT-qPCR analysis at 24 and 48 h intervals. Table I summarizes the upregulated/downregulated genes detected following treatment of OSC2 cells with IFNγ. As shown in Fig. 2, DSPP, MMP20, GRP78, SERCA2b and, to a lesser extent, IRE1, exhibited statistically significant differences (P<0.05). These results suggested that IFNγ treatment
may affect ER Ca homeostasis by suppressing SERCA2b and inducing IP3r. Furthermore, the results suggested that the IFNγ-induced downregulation of GRP78, and the modest effects on UPR-associated proteins IRE1 and PERK, may induce ER stress.

**IFNγ treatment decreases OSC2 cell migration.** To assess the effects of IFNγ treatment on the migratory capacity of OSC2 cells, the rate of scratch wound closure on cell culture plates was determined. As shown in Fig. 3, IFNγ treatment of cells significantly delayed wound closure compared with the control cells at 24 and 48 h (P<0.05). This finding may be associated with the significantly reduced MMP20 mRNA expression detected in IFNγ-treated cells compared with the control cells (P<0.05; Fig. 2), and suggested that IFNγ may regulate the migratory capacity of OSC2 cells, possibly by suppressing MMP20 along with its cognate partner DSPP.

**IFNγ treatment inhibits proliferation and increases apoptosis of OSC2 cells.** To analyze mitochondrial activity following treatment of OSC2 cells with IFNγ for various time-points, the MTT colorimetric assay was conducted. As shown in Fig. 4, IFNγ-treated cells exhibited significantly lower OD values at 24 and 48 h compared with the control cells (P<0.05), thus indicating that OSC2 cell proliferation was reduced following IFNγ treatment. This observation is consistent with the results of western blotting; IFNγ treatment induced a reduction in the expression levels of the cell proliferation-associated marker PCNA (Fig. 5). In order to assess the rate of apoptosis, IFNγ-treated OSC2 cells were analyzed by Annexin V-FITC flow cytometry and apoptotic rates were compared with the control (untreated) group. Cell sorting indicated that the apoptotic cell fraction was significantly increased from 3.51% in the untreated control group to 16.8 and 27.6% in IFNγ-treated cells at 24 and 48 h, respectively (Fig. 6). This finding is consistent with the upregulation in the protein expression levels of pro-apoptotic molecules, Bax and cytochrome c, and the downregulation of the anti-apoptotic molecule, Bcl-2, as shown in Fig. 5. Taken together, these results suggested that...
IFN\(\gamma\) may exert an antitumor effect on OSCC cells by reducing cell proliferation and enhancing apoptosis.

**Discussion**

To the best of our knowledge, the present study is the first to determine the various effects of IFN\(\gamma\) treatment on the mRNA expression levels of DSPP and MMP20, ER Ca homeostasis, ER stress- and UPR-associated proteins, and on notable hallmarks of oral carcinogenesis in OSCC cells. The downregulation of DSPP and MMP20 mRNA expression following IFN\(\gamma\) treatment may account for the reduced migratory potential of OSC2 cells. Our previous report revealed that the strong binding of DSP to MMP20, and its interaction with the promoter proximal element of MMP20, may account for increased migration, invasion and metastasis in OSCC (32). Recently, we reported that DSPP silencing results in significantly reduced MMP20 mRNA expression and in reduced migration of OSCC (34). Other investigators have reported that IFN\(\gamma\) and IFN\(\beta\) suppress MMP9 expression through a signal transducer and activator of transcription (STAT)\(1\alpha\) pathway in primary astrocytes and human fibrosarcoma cells (36), and that IFN\(\gamma\) treatment reduces migration of A172 human glioblastoma cells (37). IFN\(\gamma\) also inhibits MMP3-induced invasiveness of T98G glioma cells (38). Therefore, the effects of DSPP and MMP20 downregulation on the notable hallmarks of oral carcinogenesis, including decreased cell viability and migration, and increased apoptosis, noted in the present study...
following treatment of OSC2 cells with IFNγ are consistent with our previous findings (33,34).

It has previously been suggested that IFNs enhance apoptosis in acute promyelocytic leukemia, chronic myelogenous leukemia, multiple myeloma, melanoma and ovarian cancer (39). Specifically, several reports have highlighted the effects of IFNγ on head and neck squamous cell carcinoma (HNSCC) cells. For example, a recent report revealed that IFNγ induces apoptosis in two HNSCC cell lines, and leads to overexpression and activation of inositolamine 2,3 protein (13). Furthermore, IFNγ activates Janus kinase/STAT1, apoptosis signal-regulating kinase 1, p38, c-jun-N-terminal kinase, the nuclear factor-xB pathway and IRF1 (13). IFNγ treatment of OSCC cells has also been revealed to result in down-regulation of heat shock protein 27, which is a proposed anti-apoptotic molecule, and enhancement of cell death (40).

Gadkaree et al reported that the antitumor effects of synthetic cyclic dinucleotides are associated with the upregulation of IFN-γ cluster of differentiation 8 infiltrating T cells and programmed death-L1 protein in a HNSCC xenograft-mouse model (41). Xu et al revealed that IFNγ sensitizes HNSCC cells to chemotherapy-induced apoptosis and necroptosis by upregulating early growth response protein 1 (42). Conversely, administration of IFNα or tumor necrosis factor α does not induce considerable alterations in OSCC apoptosis (40).

The present results suggested that IFNγ treatment of OSC2 cells suppressed PCNA and Bcl-2 expression, and upregulated Bax and cytochrome c expression; these findings are consistent with previous report of similar effects in human breast, prostate and lung cancer cells. Ning et al reported that IFNγ, but not IFNα or IFNβ, enhances IRF1 expression in anti-estrogen-resistant human breast cancer cells, and IRF1 induction downregulates the expression of pro-survival proteins, Bcl-2 and Bcl-2-like protein 2, and enhances pro-apoptotic Bcl-2 antagonist/killer (Bak) and Bax activity (43). Furthermore, IFNγ enhances the apoptotic effects of polyinosinic:polycytidylic acid in human prostate cancer cells by enhancing Bak expression (44). With regards to human lung cancer cells, IFNγ induces phosphorylated-STAT1 activity in cells expressing STAT1-CC, which are hyper-responsive to IFN, thus resulting in downregulation of PCNA and c-fos (45). In OSCC cells of the tongue, Liu et al reported that overexpression of interleukin-18 activates caspase-3, -7 and -9 pathways, and enhances IFNγ and cytochrome c mRNA expression (46).

With regards to ER Ca homeostasis-, ER stress- and UPR-associated proteins, the present data revealed that IFNγ treatment decreased GRP78 and SERCA2b mRNA expression, and induced IP3r expression. These findings supported the hypothesis that a combination of increased ER Ca leakage (through IP3 channels) and a blockage in Ca influx (via suppression of SERCA activity) may perturb ER Ca homeostasis and enhance ER stress. Furthermore, the high apoptotic rates observed in response to IFNγ treatment of OSC2 cells may be associated with GRP78 downregulation. This speculation is based on the results of previous studies, which provide evidence indicating that GRP78 promotes tumor progression (47,48), and increased GRP78 expression is correlated with shorter recurrence time and poor survival of patients with prostate and breast cancers (49-51). Notably, in response to GRP78 inhibition, the response of patients with prostate cancer to photodynamic therapy is improved (52). In vitro and animal experiments, GRP78 silencing suppresses tumor cell invasion, cell growth and metastasis in xenograft models of gastric cancer (53).

The present data also indicated that IFNγ treatment resulted in moderate downregulation of IRE1 mRNA expression, and a very modest induction of PERK activity after 48 h. These findings are consistent with earlier reports indicating that treatment of pancreatic rat cells with IFNγ decreases the basal levels of spliced X-binding protein 1 (XBP1) mRNA; XBP1 is downstream of IRE1 (14). Similarly, Son et al reported that IRE1 silencing results in accelerated Ca efflux through IP3r and increased apoptotic rates in human neuroblastoma cells (54), whereas Kanekura et al indicated that IRE1 inhibition enhances ER stress and apoptosis through oligomerization of Bax and Bak proteins (55). With regards to HNSCC cells, an in vitro study by El Jamal et al suggested that IFNγ treatment of HNSCC cells triggers ER stress and induces apoptosis by upregulating PERK and IRE1 pathways (13). Furthermore, Fribley et al demonstrated that treatment with Celastrol (a triterpenoid compound isolated from the Celastraceae plant family) mediates the pro-apoptotic UPR effects and apoptosis in OSCC cells via PERK-eukaryotic translation initiation factor 2 (eIF2)-ATF4-C/EBP homologous protein signaling (56). Similarly, Afatinn, which is an inhibitor that targets ErbB family members, triggers the PERK-eIF2α-ATF4 pathway and suppresses protein kinase B-mammalian target of rapamycin activity leading to apoptosis of HNSCC cells (57).

Notably, some studies appear to conflict with the aforementioned findings, suggesting a tumorigenic role for PERK in modulation of ER stress. For example, Fujimoto et al reported that PERK inhibition induces apoptosis of cancer stem cells (58), whereas Koumenis reported that the expression of PERK, and its target molecule eIF2, are correlated with increased tumor growth and survival under hypoxic conditions (59). Furthermore, it has been reported that PERK inhibition decreases tumor growth in vitro and in vivo (60), and hampers metastasis in breast cancer mice xenografts (61).

Our previous study suggested the effects of DSPP on ER stress, the UPR and Ca homeostasis (34), and the present data indicated that treatment of OSC2 cells with IFNγ resulted in downregulation of DSPP and MMP20; therefore, it may be hypothesized that DSPP serves an oncogenic role during the ER stress adaptive response in the OSCC microenvironment. Therefore, IFNγ treatment-induced DSPP downregulation may be directly associated with the observed alterations in ER homeostasis, at least partially by mediating alterations in major ER stress-associated proteins, including GRP78, SERCA2b and UPR sensor proteins, thus contributing to UPR collapse. Although the mechanisms by which IFNγ interacts with DSPP are yet to be fully understood, these mechanisms may include pathways that are yet to be characterized. Overall, the finding that IFNγ modified OSCC properties through UPR modifications warrants further investigation.

It has been suggested that the UPR serves a dual role in cancer biology: Firstly, to ameliorate ER stress-associated damage; and secondly, to activate apoptotic pathways in severe conditions (22). For this reason, it is often difficult to predict whether, or for how long, UPR proteins inhibit tumor growth, or protect cancer cells within the tumor microenvironment (62).
It would appear that the duration and severity of ER stress determines the survival or apoptotic death of cancer cells (62). Conflicting reports regarding the effects of UPR protein expression on cancer cell fate may reflect the fact that individual UPR protein modifications result in opposing signals between induction and attenuation under ER stress (62,63).

In conclusion, the present data strongly supported an anti-tumor role for IFN-γ in OSCC cells through mechanisms that downregulate DSPP and MMP20, leading to disturbances in ER homeostasis, and alterations in proteins associated with ER stress and Ca²⁺ regulation. Notably, treatment of OSCC cells with IFN-γ also decreased cell viability and migration, and increased apoptosis. Therefore, it may be speculated that either IFN-γ interacts with DSPP, which, in turn, at least partially mediates the observed effects on ER stress molecules, or, alternatively, DSPP modifications follow IFN-γ treatment-induced alterations in ER homeostasis. A recognized limitation of the present study is the focus on the alterations in the mRNA expression levels of genes encoding ER stress- or UPR-associated proteins. Nevertheless, the data obtained presents background information for the design of additional studies investigating alterations in protein expression and related functional mechanisms. Therefore, further studies beyond the scope of the present report may help to elucidate the sequential mechanisms underlying IFN-γ-DSPP interaction in OSCC, and the consequential effects on ER stress response. These studies aim to provide insight into potential targeted therapeutic methods and interventional strategies for the treatment of patients with OSCC.

Acknowledgements

Not applicable.

Funding

This study was supported by faculty startup research funding (to KUEO) from the University of Texas Health Science Center at Houston (Houston, TX, USA).

Availability of data and materials

The datasets used and/or analyzed in the present study are available from the corresponding author on reasonable request.

Authors’ contributions

NGN and KUEO made substantial contributions to the conception and design of the study, reviewed data, reviewed/edit draft manuscripts, and reviewed/edit the final draft of the manuscript. IG and JA carried out experiments related to the study, acquired, analyzed and interpreted data, and provided the initial draft of the manuscript. All authors gave their approval of the final draft of the manuscript, and agree to be accountable for all aspects of the study related to accuracy or integrity of all parts of the study.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Irani S: Distant metastasis from oral cancer: A review and molecular biologic aspects. J Int Soc Prev Community Dent 6: 265-271, 2016.
2. Guaid EP, Torre LA and Jamal A: International trends in head and neck cancer incidence rates: Differences by country, sex and anatomic site. Oral Oncol 50: 387-403, 2014.
3. Russo D, Merolla F, Mascolo M, Iliardi G, Romano S, Varricchio S, Napolitano V, Celetti A, Postiglione L, Di Lorenzo PF, et al: FKBP51 immunohistochemical expression: A new prognostic biomarker for OSCC? Int J Mol Sci 18: 443, 2017.
4. Silverman SJ: Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 132 (Suppl): S7-S11, 2001.
5. Kujan O, Glenny AM, Duxbury J, Thakker N and Sloan P: Evolution of screening strategies for improving oral cancer mortality: A Cochrane systematic review. J Dent Educ 69: 255-265, 2005.
6. Wakita D, Chamoto K, Ohkuri T, Narita Y, Ashino S, Sumida K, Nishikawa H, Shiiku H, Togashi Y, Kitamura H, et al: IFN-γ-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 30: 1408-1415, 2009.
7. Hayakawa Y, Sato-Matsushita M, Takeda K, Iwakura Y, Tahara H and Irimura T: Early activation and interferon-γ production of tumor-infiltrating mature natural killer cells. Cancer Sci 102: 1967-1971, 2011.
8. Hong M, Jiang Z and Zhou YF: Effects of therapy on Th1/Th2 cells in esophageal cancer patients treated with radiotherapy. Asian Pac J Cancer Prev 15: 2359-2362, 2014.
9. Chen J, Hou J, Zhang J, An Y, Zhang X, Yue L, Liu J and Li X: Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity. Eur J Pharmacol 682: 161-170, 2012.
10. Gattoni A, Parmato A, Vangieri B, Bresciani M and Derna R: Interferon-gamma: Biological functions and HCV therapy (type I/ll) (1 of 2 parts). Clin Ter 157: 377-386, 2006.
11. Chung TW, Tan KT, Chan HL, Lai MD, Yen MC, Li YR, Lin SH and Lin CC: Induction of indoleamine-2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cells. Asian Pac J Cancer Prev 15: 7995-8001, 2014.
12. Hastie C: Interferon-gamma, a possible therapeutic approach for late-stage prostate cancer? Anticancer Res 28B: 2843-2849, 2008.
13. El Jamal SM, Taylor EB, Abd Elmageed ZY, Alamodi AA, Selimovic D, Alkhateeb A, Hannig M, Hassan SY, Santourlidis S, Friedlander PL, et al: Interferon-gamma-mediated apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cells. J Int Soc Prev Community Dent 6: 255-261, 2016.
14. Piot P, Eizirik DL and Cardozo AK: Interferon-gamma potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms. Diabetologia 49: 1229-1236, 2006.
15. Watanabe Y, Suzuki O, Haruyama T and Akaike T: Early activation and interferon-γ immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 30: 1408-1415, 2009.
16. Hayakawa Y, Sato-Matsushita M, Takeda K, Iwakura Y, Tahara H and Irimura T: Early activation and interferon-γ production of tumor-infiltrating mature natural killer cells. Cancer Sci 102: 1967-1971, 2011.
17. Hong M, Jiang Z and Zhou YF: Effects of therapy on Th1/Th2 cells in esophageal cancer patients treated with radiotherapy. Asian Pac J Cancer Prev 15: 2359-2362, 2014.
18. Chen J, Hou J, Zhang J, An Y, Zhang X, Yue L, Liu J and Li X: Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity. Eur J Pharmacol 682: 161-170, 2012.
19. Gattoni A, Parmato A, Vangieri B, Bresciani M and Derna R: Interferon-gamma: Biological functions and HCV therapy (type I/ll) (1 of 2 parts). Clin Ter 157: 377-386, 2006.
20. Chung TW, Tan KT, Chan HL, Lai MD, Yen MC, Li YR, Lin SH and Lin CC: Induction of indoleamine-2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cells. Asian Pac J Cancer Prev 15: 7995-8001, 2014.
21. Hastie C: Interferon-gamma, a possible therapeutic approach for late-stage prostate cancer? Anticancer Res 28B: 2843-2849, 2008.
22. El Jamal SM, Taylor EB, Abd Elmageed ZY, Alamodi AA, Selimovic D, Alkhateeb A, Hannig M, Hassan SY, Santourlidis S, Friedlander PL, et al: Interferon-gamma-mediated apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cells. J Int Soc Prev Community Dent 6: 255-261, 2016.
23. Piot P, Eizirik DL and Cardozo AK: Interferon-gamma potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms. Diabetologia 49: 1229-1236, 2006.
24. Watanabe Y, Suzuki O, Haruyama T and Akaike T: Early activation and interferon-γ immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 30: 1408-1415, 2009.
17. Denmeade SR and Isaacs JT: The SERCA pump as a therapeutic target: Making a 'smart bomb' for prostate cancer. Cancer Biol Ther 14: 224‑2005.

18. Murtas D, Maric D, de Giorgi V, Reinboth J, Worschech A, and Ziparo E: Cancer microenvironment and endoplasmic reticulum stress response. Mediators Inflamm 2015: 417281, 2015.

19. Wang M and Kaufman RJ: The impact of the endoplasmic reticulum protein‑folding environment on cancer development. Nat Rev Cancer 14: 581‑597, 2014.

20. Yadav RK, Chae SW, Kim HR and Chae HJ: Endoplasmic reticulum stress and cancer. J Cancer Prev 19: 75‑88, 2014.

21. Bertolotti A, Zhang Y, Hendershot LM, Harding HP and Ron D: Dynamic interaction of BiP and ER stress transducers in the unfolded‑protein response. Nat Cell Biol 2: 526‑532, 2000.

22. Fisher LW and Fedarko N: Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44 (Suppl 1): 33‑40, 2003.

23. Bellahcène A, Castronovo V, Ogbreke KU, Fisher LW and Fedarko N: Small integrin‑binding ligand N‑linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer 6: 212‑226, 2006.

24. Ogbreke KU, Nikitakis NG, Warburton G, Ord RA, Sauk JJ, Waller JL and Fisher LW: Up‑regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral Oncol 43: 920‑932, 2007.

25. Ogbreke KU, Abdelsayed RA, Kushner H, Li L and Fisher LW: Two members of the SIBLING family of proteins, DSPP and BSP, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma. Cancer 116: 1709‑1717, 2010.

26. Annnobi CC, Koli K, Saxena G, Banjo AA and Ogbreke KU: Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms. Oncotarget 7: 48038‑48049, 2016.

27. Ogbreke KU, Weinberger PM, Looney SW, Li L and Fisher LW: Expressions of matrix metalloproteinase‑9 (MMP‑9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically similar margins may predict recurrence of oral squamous cell carcinoma. Oncotarget 3: 286‑298, 2012.

28. Saxena G, Koli K, de la Garza J and Ogbreke KU: Matrix metalloproteinase 20‑dentin sialophosphoprotein interaction in oral cancer. J Dent Res 94: 584‑593, 2015.

29. Joshi R, Tawfik A, Edel N, McCloud V, Looney S, Lewis J, Hsu S and Ogbreke KU: Dentin sialophosphoprotein (DSPP) gene‑silencing inhibits key tumorigenic activities in human oral cancer cell line, OSC2. PLoS One 5: e13974, 2010.

30. Gkouveris I, Nikitakis NG, Aservatham J and Ogbreke KUE: The tumorigenic role of DSPP and its potential regulation of the unfolded protein response and ER stress in oral cancer cells. Int J Oncol 53: 1743‑1751, 2018.

31. Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, and Ziparo E: Cancer microenvironment and endoplasmic reticulum stress response. Mediators Inflamm 2015: 417281, 2015.

32. Ma Z, Qin H and Benveniste EN: Transcriptional suppression of matrix metalloproteinase‑9 gene expression by IFN‑gamma and IFN‑beta: Critical role of STAT‑1alpha. J Immunol 167: 2849‑2859, 2001.

33. Knüpfert MM, Knüpfert H, Jendrossek V, Van Gool S, Wolff JE and Keller E: Interferon‑gamma induces growth and migration of A172 human glioblastoma cells. Anticancer Res 21A: 3989‑3994, 2001.

34. Cheng SM, Xing X, Li JC, Cheung BK and Lau AS: Interferon‑gamma regulation of TIMP‑1, TIMP‑2, and MMP‑9 expression and migration of human glioma T98G cells. Int J Cancer 121: 1190‑1196, 2007.

35. Chawla‑Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH and Borden EC: Apoptosis and interferons: Role of interferon‑stimulated genes as mediators of apoptosis. Oncogene 27: 2237‑241, 2008.

36. Yonekura N, Yokota S, Yonekura K, Dehari H, Arata S, Kohama G and Fuji N: Interferon‑gamma downregulates Hsp27 expression and suppresses the negative regulation of cell death in oral squamous cell carcinoma lines. Cell Death Differ 10: 212‑223, 2003.

37. Gadkaree SK, Fu J, Sen R, Korrer MI, Allen C and Kim YJ: Induction of tumor regression by intratumoral STING agonists combined with anti‑programmed death‑1 blocking antibody in a preclinical squamous cell carcinoma model. Head Neck 39: 1086‑1094, 2017.

38. Xu B, Shu Y and Liu P: INF‑γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy‑induced apoptosis and necroptosis through up‑regulation of Egr‑1. Histol Histopathol 29: 1437‑1443, 2014.

39. Ning Y, Riggins RB, Mullia JE, Chung H, Zwart A and Clarke R: IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1. IFN regulatory factor 1, NF‐kappaB, BCL2 family members, and signaling to caspase‑dependent apoptosis. Mol Cancer Ther 9: 1274‑1285, 2010.

40. Tan H, Zeng C, Xie J, Alghamdi NJ, Song Y, Zhang H, Zhou A and Jin D: Effects of interferons and double‑stranded RNA on human prostate cancer cell apoptosis. Oncotarget 6: 39184‑39195, 2015.

41. Chen J, Zhao J, Chen L, Dong N, Ying Z, Cai Z, Ji D, Zhang Y, Dong L, Li Y, et al: STAT1 modification improves therapeutic effects of interferons on lung cancer cells. J Transl Med 13: 293, 2015.

42. Liu W, Hu M, Wang Y, Sun B, Guo Y, Xu Z, Li J and Han B: OVERexpression of interleukin‑18 protein reduces viability and induces apoptosis of tongue squamous cell carcinoma cells by activation of glycosynth kinase‑3β signaling. Oncol Rep 33: 1049‑1056, 2015.

43. Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, Mao C, Ye R, Wang M, Pen L, et al: Critical role of the stress chaperon GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene‑induced mammary tumor development. Cancer Res 68: 498‑508, 2008.

44. Fu Y, Wey S, Wang M, Ye R, Liao CP, Roy‑Burrman P and Lee AS: Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperon GRP78/BiP in prostate epithelium. Proc Natl Acad Sci USA 105: 19444‑19449, 2008.

45. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groschen S, Lieskovsky G, Skinner DG, et al: Glucose‑regulated protein GRP78 is up‑regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 38: 1547‑1552, 2007.

46. Ok K, Shaqizamani NA, Wärri A, Jin L, Hikakivi‑Clarke LA and Clarke R: Glucose‑regulated protein 78 controls cross‑talk between apoptosis and autophagy to determine antisteatogenic responsiveness. Cancer Res 72: 3337‑3349, 2012.

47. Lee E, Nichols P, Spencer D, Groschen S, Yu MC and Lee AS: GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66: 7849‑7853, 2006.

48. Fireczuk M, Gabrysiak M, Barankiewicz J, Domagala A, Nowis D, Kujawa M, Jankowska‑Steifer E, Wachowska M, Glodkowska‑Mrowka E, Korsak B, et al: GRP78‑targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis 5: e12411, 2014.

49. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, Wei D, Yao J, Fang S and Xie K: Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis 23: 401‑410, 2006.

50. Son SM, Byun J, Roh SE, Kim SJ and Mook‑Jung I: Reduced IRF1 mediates apoptotic cell death by disrupting calcium homeostasis via the InsP3 receptor. Cell Death Dis 5: e1188, 2014.

51. Kanekura K, Ma X, Murphy JT, Zhu LJ, Diwan A and Uranoff F: IRF1 prevents endoplasmic reticulum membrane permeabilization and cell death under pathological conditions. Sci Signal 8: ra62, 2015.

52. Fribley AM, Miller JR, Brocelli AL, Garshott DM, Zeng Q, Ritter TE, Narula N, Cai P, Xi Y, Callaghan ML, et al: Celastrol induces unfolded protein response‑dependent cell death in head and neck cancer. Exp Cell Res 330: 412‑422, 2015.
57. Liu X, Lv Z, Zou J, Liu X, Ma J, Wang J, Sa N, Jing P and Xu W: Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma. Am J Cancer Res 6: 1708-1719, 2016.

58. Fujimoto A, Kawanaka K, Taguchi A, Adachi K, Sato M, Nakamura H, Ogishima J, Yoshida M, Inoue T, Nishida H, et al: Inhibition of endoplasmic reticulum (ER) stress sensors sensitizes cancer stem-like cells to ER stress-mediated apoptosis. Oncotarget 7: 51854-51864, 2016.

59. Koumenis C: ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 6: 55-69, 2006.

60. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T, et al: Discovery of 7-methyl-5-[[3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-1H-indol-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 55: 7193-7207, 2012.

61. Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, Cavener D and Diehl JA: PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 29: 3881-3895, 2010.

62. Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F and Van Vlierberghe H: The paradox of the unfolded protein response in cancer. Anticancer Res 33: 4683-4694, 2013.

63. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM and Walter P: IRE1 signaling affects cell fate during the unfolded protein response. Science 318: 944-949, 2007.